Glaucoma Associates of New York
New York, 10003, United States
NCT Number: NCT00570726
This study was designed to evaluate the efficacy and safety in the use of Ranibizumab, an effective vascular endothelial growth factor (VGEF) inhibitor, in treating patients with a failing bleb, characterized by increased fibrosis and vascularization of the conjuctiva, following trabeculectomy. Six subjects from one site will be enrolled in this study.
Looking for future studies?
Notify Me40 year and older
All sexes
Interventional
Phase 1
New York, 10003, United States
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The New York Eye & Ear Infirmary
Other
Effect of Needle Bleb Revision With Ranibizumab as a Primary Intervention in a Failing Bleb Following Trabeculectomy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05236439
Eye Diseases, Glaucoma
Yerevan, Armenia
View Trial DetailsNCT05325996
Eye Diseases, Glaucoma
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT04872348
Eye Diseases, Glaucoma
Atlanta, Georgia, United States
View Trial DetailsNCT04944290
Eye Diseases, Glaucoma
Winston-Salem, North Carolina, United States
View Trial Details